H influenzae & M catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation

Kian Fan Chung¹, Ali Versi¹, Fransiskus Xaverius Ivan², Mahmoud Ibrahim³, Stewart Bates⁴, John Riley⁴, Frederic Baribaud⁵, Nazanin Zounemat Kermani¹, Paolo Montuschi⁶, Sven-Erik Dahlén⁷, Ratko Djukanovic⁸, Peter Sterk³, Anke-Hilse Maitland-van der Zee³, Sanjay Haresh Chotirmall², Peter Howarth⁹, and Ian Adcock¹

¹Imperial College London National Heart and Lung Institute
²Lee Kong Chian School of Medicine
³Amsterdam University Medical Centers
⁴GSK
⁵Janssen Research and Development High Wycombe
⁶Catholic University of the Sacred Heart
⁷Karolinska Institutet
⁸NIHR Southampton Biomedical Research Centre
⁹University of Southampton Faculty of Medicine

December 29, 2022

Abstract

Background. Because of altered airway microbiome in asthma, we analysed the bacterial species in sputum of patients with severe asthma. Methods. Whole genome sequencing was performed on induced sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate asthma (MMA) and healthy controls (HC). Data was analysed by asthma severity, inflammatory status and transcriptome-associated clusters (TACs). Results. α -diversity at the species level was lower in SAn and SAs/ex, with an increase in Haemophilus influenzae and Moraxella catarrhalis, and Haemophilus influenzae and Tropheryma whipplei, respectively, compared to HC. In neutrophilic asthma, there was greater abundance of Haemophilus influenzae and Moraxella catarrhalis and in eosinophilic asthma, Tropheryma whipplei was increased. There was a reduction in α -diversity in TAC1 and TAC2 that expressed high levels of Haemophilus influenzae and Tropheryma whipplei, and Haemophilus influenzae and Moraxella catarrhalis, respectively, compared to HC. Sputum neutrophils correlated positively with Moraxella catarrhalis and negatively with Prevotella, Neisseria and Veillonella species and Haemophilus parainfluenzae. Sputum eosinophils correlated positively with Tropheryma whipplei which correlated with pack-years of smoking. α - and β diversities were stable at one year. Conclusions. Haemophilus influenzae and Moraxella catarrhalis were more abundant in severe neutrophilic asthma and TAC2 linked to inflammasome and neutrophil activation, while Haemophilus influenzae and Tropheryma whipplei were highest in SAs/ex and in TAC1 associated with highest expression of IL-13 Type 2 and ILC2 signatures with the abundance of Tropheryma whipplei correlating positively with sputum eosinophils. Whether these bacterial species drive the inflammatory response in asthma needs evaluation.

H influenzae & M catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation

Ali Versi^{1*}, Fransiskus Xaverius Ivan^{2*}, Mahmoud I Abdel-Aziz³, Stewart Bates⁴, John Riley⁴, Frederic Baribaud⁵, Nazanin Zounemat Kermani¹, Paolo Montuschi⁶, Sven-Erik Dahlen⁷, Ratko Djukanovic⁸, Peter

Sterk³, Anke-Hilse Maitland-Van Der Zee³, Sanjay H Chotirmall^{2, 9}, Peter Howarth⁸, Ian M Adcock¹, Kian Fan Chung¹, on behalf of U-BIOPRED consortium.

¹National Heart & Lung Institute & Data Science Institute, Imperial College London, United Kingdom;²Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore;³Amsterdam University Medical Centers, Department of Respiratory Medicine, University of Amsterdam, Amsterdam, Netherlands;⁴Respiratory Therapeutic Unit, GSK, Stockley Park, UK;⁵Janssen Research and Development, High Wycombe, Buckinghamshire, United Kingdom; ⁶Department of Pharmacology, Catholic University of the Sacred Heart, Rome, Italy;⁷Centre for Allergy Research, Karolinska Institute, Stockholm, Sweden; ⁸Faculty of Medicine, Southampton University, Southampton, UK and NIHR Southampton Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK;⁹Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.

*Equal contribution

Running title : H influenzae and M catarrhalis in severe asthma

3500 words; 5 Figures.

Supplementary Data: Supplementary Tables 1 to 3, Supplementary Figures 1-6.

Address for correspondence:

Professor K F Chung, National Heart & Lung Institute, Imperial College London, Dovehouse St, London SW3 6LY UK

f.chung@imperial.ac.uk

Abstract 248 w

Background. Because of altered airway microbiome in asthma, we analysed the bacterial species in sputum of patients with severe asthma.

Methods. Whole genome sequencing was performed on induced sputum from non-smoking (SAn) and current or ex-smoker (SAs/ex) severe asthma patients, mild/moderate asthma (MMA) and healthy controls (HC). Data was analysed by asthma severity, inflammatory status and transcriptome-associated clusters (TACs).

Results. α -diversity at the species level was lower in SAn and SAs/ex, with an increase in Haemophilus influenzae and Moraxella catarrhalis, and Haemophilus influenzae and Tropheryma whipplei, respectively, compared to HC. In neutrophilic asthma, there was greater abundance of Haemophilus influenzae and Moraxella catarrhalis and in eosinophilic asthma, Tropheryma whipplei was increased. There was a reduction in α -diversity in TAC1 and TAC2 that expressed high levels of Haemophilus influenzae and Tropheryma whipplei, and Haemophilus influenzae and Moraxella catarrhalis , respectively, compared to HC. Sputum neutrophils correlated positively with Moraxella catarrhalis and negatively with Prevotella ,Neisseria and Veillonella species and Haemophilus parainfluenzae . Sputum eosinophils correlated positively with Tropheryma whipplei which correlated with pack-years of smoking. α - and β -diversities were stable at one year.

Conclusions. Haemophilus influenzae and Moraxella catarrhalis were more abundant in severe neutrophilic asthma and TAC2 linked to inflammasome and neutrophil activation, while Haemophilus influenzae and Tropheryma whipplei were highest in SAs/ex and in TAC1 associated with highest expression of IL-13 Type 2 and ILC2 signatures with the abundance of Tropheryma whipplei correlating positively with sputum eosinophils. Whether these bacterial species drive the inflammatory response in asthma needs evaluation.

Key words

Severe asthma, α-diversity, Haemophilus influenzae, Moraxella catarrhalis, Tropheryma whipplei.

Introduction

Severe asthma is a heterogeneous condition that can be differentiated into clinical, and molecular inflammatory phenotypes (1). The severe eosinophilic asthma cluster is the most established inflammatory phenotype linked to Type 2 inflammation driven by cytokines such as IL-4, IL-5 and IL-13 (2). On the other hand, the neutrophilic inflammatory phenotype characterized by sputum neutrophilia is associated with Type 1 inflammatory pathways and inflammasome activation (3). While there has been a link between inflammasome activation and neutrophil airway recruitment in asthma (4), the mechanism driving neutrophil recruitment and activation remains unclear. Because of the ability of airway microbial organisms to induce inflammatory responses, the complex lung microbiome may contribute to clinical and inflammatory phenotypes of asthma (5, 6).

Detailed analysis of the microbial community composition in asthma has been made possible by using culture-independent techniques such as 16S ribosomal RNA microarray and PCR. Proteobacteria families are enriched in airway microbiota of asthma patients (7) and have been associated with airway hyperresponsiveness and worsening asthma control (8). Streptococcus pneumoniae, Moraxella catarrhalis (9, 10), and Haemophilus influenzae (7, 9, 11) have been reported in patients with stable asthma. Neutrophilic asthma has been associated with enriched Proteobacteria (12), including Moraxella and Haemophilus (13), and in particular Haemophilus influenzae(12). Reduced sputum bacterial diversity has been reported in neutrophilic asthma as compared with other asthma phenotypes (12, 13).

For the first time, we have undertaken a metagenomic whole genome sequencing approach of induced sputum from patients with asthma that has the added advantage of providing an in-depth characterization and insights into the microbiome down to the species level in order to understand the relationship between airway dysbiosis and airway inflammation. We have examined the effect of asthma severity and granulocytic inflammation on the abundance of microbial species. We also examined the relationship of the molecular phenotype of asthma to the bacterial species abundance that provides the potential links between these species and the host immunological and inflammatory responses (14).

Methods

Participants

The U-BIOPRED severe asthma cohort consisted of two groups of adult severe asthmatics: non-smokers (SAn), and smokers or ex-smokers (SAs/ex) together with non-smoking mild-moderate asthma (MMA) and non-smoking healthy volunteers (HC), as previously described (15). Participants provided induced sputum samples that passed quality control for metagenomic analysis (16), at baseline and at 12-16 months later. Ethics approval was obtained at the 14 participating centres and all participants gave written informed consent (ClinicalTrials.gov identifier: NCT01982162).

Induction and initial sample handling

Sputum induction was undertaken and processed as previously described (15). Frozen sputum samples were sent to Second Genome (San Francisco, California, USA) for metagenomic sequencing. Genomic DNA was extracted using the MoBio Tissue and Cells DNA Isolation Kit (Qiagen, Germantown, USA) at 250µl input volume, performed in a BioSafety Cabinet in an ISO8 Cleanroom. Each batch included negative and positive controls, as described previously (17). Extracted DNA was stored at -20°C. Samples were prepared for sequencing with the Illumina Nextera kit (Illumina, San Diego, USA) and quantified with Quant-iT dsDNA High Sensitivity assays (ThermoFisher Scientific, Waltham, USA). Libraries were pooled and run with 100 base-pairs paired-end sequencing protocols on the Illumina HiSeq 2500 platform.

Quality control of metagenomic data and host reads removal

FastQC version 0.11.8 (17) was used to check the quality of the original sequencing reads. Then, bowtie2 version 2.3.5.1 (with its default parameters)(18) was used to align the quality-filtered reads to the human reference genome (hg38[https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/])). Unmapped, non-host reads were separated from host reads and sorted using samtools version 1.9 (19). The output files, which were in BAM format, were converted into fastq files using bedtools version 2.28 (20) and then into

fasta files using R/Bioconductor package ShortRead version 3.6.2 (21). Non-host metagenomic reads of each sputum sample were subjected to bioinformatics pipelines that generate microbiome and functional profiles. We used MetaPhlAn2 version 2.7.7 and its marker database (22) to estimate microbiome profiles (viruses were excluded from the output).

Statistical and computational analyses

Microbial pathways were analysed with reference to the UniPathway database (23). The R languages' vegan package was used for calculating Shannon's index within sample diversity, α -diversity (24), and Bray-Curtis dissimilarity between microbiome and microbial pathway sample pairs. Similarity between pairs of profiles were calculated as 1-d, where d is the associated Bray-Curtis dissimilarity. These dissimilarity matrices were used to evaluate sample-to sample diversity, β -diversity, between cohorts and timepoints using the permutational multivariate analysis of variance (PERMANOVA) implemented in vegan's ADONIS function, as well as to visualize the relationship between sample groups using the principal coordinate analysis implemented in R's phyloseq package (25). When PERMANOVA analysis gave a significant result, the R's DESeq2 package (26) with test and fitType parameters set to "Wald" and "parametric", and with pseudocount of 1 addition to phylum-/genus-/species-level MetaPhlAn2 RPKM data, were used to identify differentially-abundant microbiome taxa and microbial pathways. The p-values following Wald test were corrected for multiple testing using the Benjamini-Hochberg method.

Kruskal-Wallis test was employed to assess differences between groups at the taxonomic pathway level. When a significant difference was obtained, the Mann-Whitney U test with a Holm-Bonferroni correction was used for post-hoc comparisons. Wilcoxon Signed-Rank test was used to test differences in alpha-diversity over time using paired baseline and longitudinal follow-up. Spearman correlations were used to determine the relationship between microbiome abundance and clinical traits and inflammatory biomarkers. All statistical tests performed were two-tailed.

Results

Table S1 summarises the clinical and physiological characteristics and Tables S2 and S3 the asthma participants according to granulocytic inflammation status and to molecular phenotype, respectively. Using MetaPhlAn2, out of 193 sputum samples, 189 were available for species-level analysis. Although 46 sputum samples were analysed at follow-up, there were paired samples for baseline and longitudinal analyses in only 33 subjects. We also analysed the results in terms of the granulocytic inflammation defined by the level of sputum eosinophils and neutrophils (16) (Table S2) and of the molecular phenotypes defined as transcriptomic-associated clusters (TACs) (Table S3) (14). The molecular pathways characterising the 3 TACs is shown in Table S4.

Metagenomic sequencing

The depth of metagenomic sequencing of the 190 sputum samples before host reads removal is shown in **Figure S1A**. Excluding one sample with a very low depth of 11,204 reads (left-most), the sequencing depth ranged from 9.1 million to 63.6 million reads, with a median and an interquartile range of 33.3 million and 17.2 million reads, respectively. Following host reads removal, the range of the depth of non-host sequencing reads had median of ~1,5 million reads. Airway microbiome data, excluding 5 samples whose reads were not assigned to any phylum by MetaPhlAn2, were assessed at phylum-level (**Figure S1B**). The sequencing depth did not influence airway microbiome profile (**Figure S1C**). Four bacterial phyla, *Bacteroidetes, Firmicutes, Proteobacteria* and *Actinobacteria*, accounted for >95% of the overall abundance (**Figure S1D**).

α - and β -diversity

Difference in airway microbiome was observed across cohorts at species level in both α -diversity (p = 0.001, **Figure 1B**) and β -diversity (p [?]0.002, **Figure 1C**). Although the levels of α -diversity in SAn and SAs/ex were comparable, SAs/ex exhibited lower α -diversity compared to MMA and HC. α -diversity of SAn was lower than that of MMA while there was no difference between MMA and HC (**Figure 1B**). α -diversity was inversely correlated with sputum neutrophils in SAn, neutrophilic and paucigranulocytic inflammation

groups, and in TAC1 and TAC3 (Figure S3). There was no positive association between α -diversity and exacerbations in the previous year or pack-years of smoking, but there was a positive correlation between α -diversity, and FEV1 (% predicted) in neutrophilic inflammation and in TAC2 (Figure S3).

Compared to HC, α -diversity was reduced in eosinophilic (p<0.05), neutrophilic (p<0.05) and mixed granulocytic (p<0.001) (**Figure 2B**). Differences in β -diversity based on Bray-Curtis dissimilarity were observed across the inflammatory groups using PERMANOVA (p<0.001) and ordination using principal coordinate analysis (**Figure 2C**).

 α -diversity in TAC1 and TAC2 was lower than in TAC3 and HC (p<0.001) (Figure 3B) . Differences in β -diversity based on Bray-Curtis dissimilarity were also observed across the TACs (p<0.001) (Figure 3C) .

Differentially-abundant genera and species by asthma grouping

Prevotella, Veillonella, Haemophilus, Neisseria, Streptococcus, Porphyromonas, Rothia, Alloprevotella, and *Tropheryma* were the major genera present in healthy subjects (**Figure S2A**).*Moraxella* and *Tropheryma* abundance was higher in SAn and SAs/ex compared to HC, respectively (**Figure S2C**).

The most abundant microbes included *Haemophilus influenzae* and *Tropheryma whipplei* (Figure 1A). The species abundance in SAn compared to MMA and HC was enhanced with *Haemophilus influenzae* and *Moraxella catarrhalis*, while in SAs/ex, *Haemophilus influenzae*, *Tropheryma whipplei*, and *Veilloneilla atypica* were enriched compared to both MMA and HC (Figure 1D). In an analysis of differences between current and ex-smokers within the SAs/ex cohort, current smokers had a lower abundance of *Haemophilus parainfluenzae* and *Neisseiria flava* compared to ex-smokers (Figure S4).

We analysed the effect of being on daily oral corticosteroid (OCS) therapy. While there was no difference in both α - and β -diversity between those on OCS and not on OCS in SAn and SAs/ex (**Figure S5**), those on OCS in SAn had lower *Haemophilus influenzae*, *Moraxella catarrhalis*, *Porphyromonas gingivalis and Porphyromonas endodontalis*, and in SAs/ex, lower *Haemophilus parainfluenzae*(**Figure S5**).

Species abundance & clinical and inflammatory features

We examined the abundance of the top 16 species with clinical and inflammatory features in the whole group of asthmatics and also in the 3 subgroups of SAn, SAs/ex and MMA (Figure 4).

Airflow obstruction . Species including those of Veillonella and Prevotella , Rothia mucilaginosa and Haemophilus parainfluenzae were positively correlated with FEV1 as an index of airflow obstruction. There was a positive correlation between Prevotella intermedia, Prevotella melaninogenica, Veillonella unclassified and Veillonella atypica in SAn, between Veillonella atypica and Prevotella melaninogenica in SAs/ex, and between Prevotella sp C561 in MMA with FEV₁ (% predicted) (Figure 4). In SAs/ex, there was a negative correlation of FEV1 (% predicted) and Haemophilus influenzae , Neisseria sicca and Trophemyra whipplei.

Exacerbations. Exacerbations in the previous year was negatively correlated with *Prevotella melaninogenica* and *Prevotella intermedia* in the whole group. This negative correlation was found with *Prevotella melaninogenica* only in SAn (**Figure 4**). In SAs/ex, there was a negative correlation with *Neisseria sicca* and a positive correlation with *Rothia mucilaginosa*.

Sputum neutrophils . In the whole group, there was a strong negative correlation of sputum neutrophils with Prevotella intermedia, Prevotella melaninogenica, Prevotella nigrescens, Alloprevotella unclassified, Haemophilus parainfluenzae, Neisseria flavescence, Neisseria sicca, Streptococcus pseudopneumoniae, Porphyromonas endodontalis, Rothia mucilaginosa, Veillonella unclassified and Veillonella atypica but a positive correlation with Moraxella catarrhalis . This was similar in SAn apart from the lack of correlation with Alloprevotella unclassified. In SAs/ex, there was negative correlation between Prevotella nigrescens and Alloprovotella unclassified , but a positive correlation between Moraxella catarrhalis and Neisseria sicca with sputum neutrophils. In MMA, a negative correlation was seen with Prevotella sp C561, Prevotella

nigrescens, Streptococcus pseudopneumoniae, Neisseria flavescens, Neisseria sicca, Rothia mucilaginosa, Haemophilus parainfluenzae and Haemophilus influenzae with sputum neutrophils.

Sputum eosinophils. There was a negative correlation between Moraxella catarrhalis, Prevotella sp C561, Prevotella nigrescens and sputum eosinophils, but a positive correlation between Tropheryma whipplei and sputum eosinophils. In SAs/ex, sputum eosinophils were negatively correlated with Rothia mucilaginosa, but positively with Tropheryma whipplei, while in SAn, with Streptococcus pseudopneumoniae and Alloprevotella unclassified (Figure 4).

Species abundance according to granulocytic inflammation

The neutrophilic group had more Haemophilus influenzae and Moraxella catarrhalis than the eosinophilic and paucigranulocytic groups, and more Moraxella catarrhalis compared to the mixed granulocytic group. Interestingly, the eosinophilic group showed more abundant Tropheryma whipplei compared to the paucigranulocytic group and HC while it had more abundant Tropheryma whipplei ,Haemophilus parainfluenzae , and other species including Prevotella pallens, Prevotella melaninogenica, Porphyromonas sp oral taxon 279 and Veillonella unclassified compared to the mixed granulocytic group (Figure 2C).

Species abundance according to TAC molecular phenotypes

As previously described (14), TAC1 is characterised by the expression of immune receptors IL-33R, CCR3R and TSLPR, TAC2 by TNF- & IFN-associated genes, and TAC3 by expression of high glucose and succinate metabolism genes (**Table S4**). There was an upregulation of *Tropheryma whipplei*, *Prevotella melanino-genica*, *Porphyromonas sp oral taxon 279*, *Prevotella histicola*, *Neiseirria unclassified*, *Veillonella unclassified* atypica but downregulation of *Moraxella catarrhalis* in TAC1 compared to TAC2, of *Haemophilus influenzae* and *Tropheryma whipplei* in TAC1 compared to TAC3, and in *Haemophilus influenzae* and *Moraxella catarrhalis* in TAC2 compared to TAC3 (**Figure 3A**, **D**). Of note *Moraxella catarrhalis* was not found in the TAC1 group. By comparison to healthy controls, TAC1 which has the highest expression score for an IL-13 Th2 and an ILC-2 signatures had an excess of *Haemophilus influenzae* and *Moraxella catarrhalis* influenzae and *Tropheryma whipplei* while TAC2 which had the highest expression scores for inflammasome and neutrophil activation an excess of *Haemophilus influenzae* and *Moraxella catarrhalis*.

Longitudinal stability of microbiome according to asthma severity

The severe asthmatics who came for follow-up visit at one year are shown in **Table S1**. The dominance of *Haemophilus influenzae* or *Tropheryma whipplei* persisted in the severe asthma subjects: 3 out of 4 subjects with *Haemophilus influenza* e dominance at baseline and 2 out of 3 subjects with *Tropheryma whipplei* dominance at baseline maintained this prevalence at longitudinal follow-up (**Figure 5**). The same trend was observed at the genus-level (**Figure S6A**).

There was no shift in α -diversity (Figure 5B) or β -diversity (Figure 5C) of airway microbiome in severe asthma cases analysed at the species or genus level. Similar results were seen at the genus level in α -diversity (Figure S6B) or β -diversity (Figure S6C). Moreover, Mann-Whitney U test with Holm correction between paired and non-paired groups showed that genus- and species-level (Figures 5D & S6D) microbiome compositional similarity between paired samples that were from the same subject was significantly higher compared to that from other possible sample pairings.

Discussion

The novelty of our analysis is being able to pin down to the microbial species level differences at the severity, inflammatory and molecular phenotype level of severe asthma using sputum metagenomic sequencing of a large cohort of patients. We focused on 3 pathogenic species, namely *Haemophilus influenzae*, *Moraxella catarrhalis* and *Tropheryma whipplei* because of their potential pathogenecity in respiratory diseases. We found reduced bacterial α -diversity of microbial species in the 2 severe asthma groups where there was higher abundance of *Haemophilus influenzae* and *Moraxella catarrhalis* in SAn compared to SAs/ex, MMA and HC, and of *Haemophilus influenzae* and *Tropheryma whipplei* in SAs/ex compared to MMA. In terms of

inflammatory status, α -diversity was lowest in the mixed granulocytic group followed by a slight reduction in the neutrophilic group, with neutrophilic inflammation associated with higher abundance of *Haemophilus influenzae* and *Moraxella catarrhalis*, while eosinophilic inflammation was associated with high abundance of *Tropheryma whipplei*. In terms of associated molecular pathways, *Haemophilus influenzae* was most abundant in TAC1 and TAC2, accompanied by an increase in *Tropheryma whipplei* in TAC1 and in *Moraxella catarrhalis* in TAC2. The abundance of *Moraxella catarrhalis* in TAC1 and TAC3 was very low. The increased abundance of *Haemophilus influenzae* in both TAC1, an eosinophilic phenotype, and in TAC2, a neutrophilic phenotype, but not in TAC3, a paucigranulocytic phenotype, is of interest. One possibility is that this increased abundance may be due to the reduced phagocytosis of *Haemophilus influenzae* by lung macrophages from patients with severe asthma (27). *Haemophilus influenzae* can induce the release of IL1 α , IL1 β , IL-6, IL-8, MCP-1 and TNF α from human tracheal epithelial cells (28), through the toll-like receptor, TLR2, activation (29), that could lead to neutrophil activation and inflammation.

In both SAn and SAs/ex, the species most positively correlated with sputum neutrophils was *Moraxella catarrhalis* while in MMA, *Haemophilus influenzae* was inversely correlated. *Moraxella catarrhalis* is a known airway pathogen that causes respiratory infections linked to neutrophilic airway inflammation in severe or poorly-controlled asthma (9, 12). *Moraxella catarrhalis* was also most abundant in the TAC2 molecular phenotype characterized by neutrophilic and inflammasome activation, supporting the possibility that it may be associated with or be responsible for the induction of neutrophilic inflammation in severe asthma. This link between *Moraxella catarrhalis* and neutrophilic inflammation is further strengthened by the highest abundance of *Moraxella catarrhalis* in TAC2 where it was positively correlated with sputum neutrophilia. This potential activating role of *Moraxella catarrhalis* is supported by its activation of TLR 2, 4 and 9 (30), induction of IL-6, IL-8 and prostaglandin E2 release through NF-xB and activation in lung epithelial cells (31, 32).

Although Tropheryma whipplei is known to cause Whipple's disease with gastrointestinal symptoms, it has also been implicated as a cause of aspiration, ventilator-associated and community-acquired pneumonia (33). Tropheryma whipplei in bronchoalveolar lavage fluid has been isolated in asymptomatic immunosuppressed patients suffering from Human Immunodeficiency virus, which was reduced by anti-retroviral therapy (34). The increased abundance of Tropherymawhipplei in SAs/ex was positively associated with sputum eosinophilia and also with pack years of smoking in the TAC1 and TAC2 phenotypes. A previous study has reported the presence of Tropheryma whipplei by PCR in sputum samples of severe asthma patients who were mainly eosinophilic (12). We found that Tropheryma whipplei was most prominent in severe asthmatics who were either current smokers or ex-smokers. These differences between NSA and SAs/ex severe asthma groups in terms of the sputum metagenome is demonstrated here for the first time. Previous studies using 16S ribosomal RNA microarray comparing the lung microbiome of smokers with non-smokers have reported either no differences (35, 36), or a higher abundance of Veillonella and Megasphaera with a decrease in Haemophilus (37). The pathogenic role of Tropheryma whipplei, if any, in SAs/ex remains unclear.

Other bacterial species were also noted to be differentially-abundant, being mainly reduced in the severe asthma groups of SAn and SAs/ex when compared to MMA and/ or HC. These include species of *Prevotella*, *Veillonella, Neisseria* and *Rothia, of* which we know little in terms of their potential lung pathogenecity. SAn and SAS/ex were different from MMA with a decreased abundance of *Prevotella intermedia* and *Rothia mucilaginosa* consistent with the previous report of decreased abundance of the genus *Prevotella* in asthma compared to non-asthmatic individuals (7, 38). Most of these species were negatively correlated with sputum neutrophilia. One bacterial species, *Haemophilus parainfluenzae*, was reduced in abundance in SAn and in TAC1 and TAC2, with negative correlation with sputum neutrophilia in SAn and MMA, and in TAC1 and TAC3. Our data indicate that *Haemophilus parainfluenzae* is decreased in current smokers compared to ex-smokers; however, since this same species is reduced also in the smoking/ex-smoking group on OCS compared to those not on OCS, it may be related to OCS therapy. *Haemophilus parainfluenzae* has been reported (39) to increase IL-8 expression with activation of p38 MAPK and inhibit corticosteroid responses in alveolar macrophages from corticosteroid-resistant asthma patients, thus may be involved in induction of

corticosteroid resistance.

Overall, the microbiome was stable when repeated at one year in severe asthma with no shift in α or β -diversity. In an unbiased microbiome-driven clustering to identify severe asthma phenotypes using the same microbial data, we found 2 distinct robust phenotypes that exhibited relative overtime stability (40). This stability does not exclude the possibility of changes in the microbiome during acute exacerbations of asthma as occurs in children where an increase in gram-negative microbes have been detected in induced sputum (41). Out of these 2 phenotypes (40), one had worse asthma outcomes, more sputum neutrophilia and greater enrichment of the gammaproteobacteria, *Haemophilus influenza* e and *Moraxella catarrhalis*. Further analysis of this phenotype has led to its association with differentially-expressed genes, in particular TNF α and related regulatory genes, the IL-1 family of interleukins, Toll-like receptors and inflammasomes (42).

We highlight some technical issues in our analysis. First, the sequencing technology of using paired-end 100 base-pairs at high sampling depth provides less accurate taxonomy profiling compared to reads of 150 base-pairs or longer at lower depth. However, we have used MetaPhlAn2 because it provides a more sensible taxonomic composition for respiratory microbiome experts compared to a protein-based method such as Kaiju (43). Secondly, the use of a marker-based approach may lead to exclusion of samples for downstream analysis due to their lack of marker genes. This is likely due to sputum having high amounts of host DNA, contributed by neutrophils and neutrophil extracellular traps resulting in low level of microbial reads, with lack of marker genes for estimating taxonomic composition, thus excluding some samples in the downstream analysis. Finally, for differential analysis, DESeq2 was used because it took into account the compositional nature of the metagenomic data, with the addition of pseudocount to overcome lack of taxa shared by all samples.

In conclusion, this sputum metagenomic study of severe asthma patients during a stable state has revealed an important association of reduced bacterial α -diversity at the species level to neutrophilic airway inflammation and neutrophil and inflammasome activation where *Haemophilus influenzae* and *Moraxella catarrhalis* were in greater abundance. On the other hand, in eosinophilic inflammation, both *Haemophilus influenzae* and *Tropheryma whipplei* were most abundant with no *Moraxella catarrhalis* found. *Tropheryma whipplei* was mostly linked to the smoking/ex-smoking severe asthma and to eosinophilic inflammation. These bacterial species may play an important role in influencing the severity and inflammatory phenotype of severe asthma, particularly linked to neutrophilic inflammation, and further studies are needed to confirm the importance of these bacteria.

Acknowledgements

U-BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in-kind contributions (www.imi.europa.eu). KFC and IMA are funded by UK Research and Innovation (UKRI). KFC is an Emeritus Senior Investigator of the UK National Institute for Health Research (NIHR). We acknowledge the contribution of the whole U-BIOPRED team as listed below.

Name	Affiliation
Abdel-Aziz MI	Department of Respiratory Medicine, Amsterdam
	UMC, University of Amsterdam, Amsterdam, The
	Netherlands
Adcock I M	National Heart and Lung Institute, Imperial
	College, London, UK;
Andersson LI	Department of Respiratory Medicine, Karolinska
	University Hospital, Stockholm, Sweden

U-BIOPRED Supplementary authors

Auffray C	European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL-INSERM, Lyon,
Badi YE,	France; National Heart and Lung Institute, Imperial College, London, UK:
Bakke P	Department of Clinical Science, University of Bergen, Bergen, Norway:
Bansal A T	Acclarogen Ltd, St. John's Innovation Centre, Cambridge, UK;
Baribaud F Bates S	Janssen R&D, LLC, Spring House, PA, USA Respiratory Therapeutic Unit, GSK, London, UK;
Bel E H	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands;
Bigler J Billing B	Previously Amgen Inc Department of Respiratory Medicine, Karolinska
Bisgaard H	University Hospital, Stockholm, Sweden COPSAC, Copenhagen Prospective Studies on
	Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Boedigheimer M J Bønnelykke K	Amgen Inc.; Thousand Oaks, USA COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark:
Brandsma J Brinkman P	University of Southampton, Southampton, UK Academic Medical Centre, University of
Bucchioni E Burg D	Chiesi Pharmaceuticals SPA, Parma, Italy Centre for Proteomic Research, Institute for Life Sciences, University of Southampton,
Bush A	National Heart and Lung Institute, Imperial College, London, UK; Royal Brompton and
Caruso M	Dept. Clinical and Experimental Medicine, University of Catania, Catania, Italy:
Chalekis R	Institute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Chanez P	Assistance publique des Hôpitaux de Marseille - Clinique des bronches, allergies et sommeil, Aix Marseille Université Marseille France
Chung F K	National Heart and Lung Institute, Imperial College London UK:
Checa T	Institute of Environmental Medicine, Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
Compton C H Corfield J Cunoosamy D	Respiratory Therapeutic Unit, GSK, London, UK Areteva R&D, Nottingham, UK; Sanofi, Cambridge, USA

D'Amico A	University of Rome 'Tor Vergata', Rome Italy;
Dahlén B	Department of Respiratory Medicine, Karolinska
	University Hospital & Centre for Allergy
	Research, Karolinska Institutet, Stockholm,
	Sweden
Dahlén S E	Institute of Environmental Medicine, Centre for
	Allergy Research, Karolinska Institutet, and
	Department of Bespiratory Medicine Karolinska
	University Hospital Stockholm Sweden
De Meulder B	European Institute for Systems Biology and
De Meulder D	Modicine CNRS ENS LICEL INSERM Lyon
	France:
Diukonovia P	NIHP Southampton Respiratory Biomodical
Djukanović K	Research Unit and Clinical and Empiricantal
	Research Unit and Unitcal and Experimental
	Sciences, Southampton, UK;
Erpendeck V J	Iransiational Medicine, Respiratory Pronting,
	Novartis Institutes for Biomedical Research,
	Basel, Switzerland;
Erzen D	Boehringer Ingelheim Pharma GmbH & Co. KG;
	Biberach, Germany
Fichtner K	Boehringer Ingelheim Pharma GmbH & Co. KG;
	Biberach, Germany
Fleming L J	National Heart and Lung Institute, Imperial
	College, London, UK; Royal Brompton and
	Harefield NHS trust, UK
Formaggio E	Previously CROMSOURCE, Verona Italy
Fowler S J	Division of infection, immunity and respiratory
	medicine, School of biological sciences, University
	of Manchester, Manchester University NHS
	Foundation Trust, Manchester Academic Health
	Science Centre, Manchester, United Kingdom
Frey U	University Children's Hospital, Basel, Switzerland;
Gahlemann M	Boehringer Ingelheim (Schweiz) GmbH,Basel,
	Switzerland;
Geiser T	Department of Respiratory Medicine, University
	Hospital Bern, Switzerland;
Goss V	NIHR Respiratory Biomedical Research Unit,
	University Hospital Southampton NHS
	Foundation Trust, Integrative Physiology and
	Critical Illness Group, Clinical and Experimental
	Sciences, Sir Henry Wellcome Laboratories,
	Faculty of Medicine, University of Southampton,
	Southampton, UK;
Guo Y	Data Science Institute, Imperial College, London,
	UK;
Hashimoto S	Academic Medical Centre, University of
	Amsterdam, Amsterdam, The Netherlands;
Haughney J	International Primary Care Respiratory Group,
	Aberdeen, Scotland;

Hedlin G	Dept. Women's and Children's Health & Centre for Allergy Research, Karolinska Institutet,
Hekking P W	Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands:
Higenbottam T	Allergy Therapeutics, West Sussex, UK;
Hohlfeld J M	Fraunhofer Institute for Toxicology and
	Experimental Medicine, Hannover, Germany
Holweg C	Respiratory and Allergy Diseases, Genentech, San Francisco, USA
Horváth I	Semmelweis University, Budapest, Hungary
Howarth P	NIHR Southampton Respiratory Biomedical
	Research Unit, Clinical and Experimental
	Sciences and Human Development and Health,
T A T	Southampton, UK
James A J	Institute of Environmental Medicine, Centre for
	Stockholm Sweden:
Knowles BG	Knowles Consulting Ltd. Stevenage UK:
Kolmert J	Institute of Environmental Medicine Centre for
	Allergy Research, Karolinska Institutet.
	Stockholm, Sweden
Konradsen J	Dept. Women's and Children's Health & Centre
	for Allergy Research, Karolinska Institutet,
	Stockholm, Sweden
Krug N	Fraunhofer Institute for Toxicology and
	Experimental Medicine, Hannover, Germany;
Lazarinis N	Department of Respiratory Medicine, Karolinska
	University Hospital & Centre for Allergy
	Research, Karolinska Institutet, Stockholm,
I: C V	Sweden Department of Medicine Selpe Verelinete
LI C-X	Institutet Steelchelm Sweden
Loza M. I	Institutet, Stockholm, Sweden
Lutter B	Academic Medical Centre University of
	Amsterdam, Amsterdam, The Netherlands:
Manta A	Roche Diagnostics GmbH, Mannheim, Germany
Masefield S	European Lung Foundation, Sheffield, UK;
Maitland-van der Zee Anke-Hilse	Department of Respiratory Medicine, Amsterdam
	UMC, University of Amsterdam, Amsterdam, The
	Netherlands;
Matthews J G	Respiratory and Allergy Diseases, Genentech, San
	Francisco, USA;
Mazem A	European Institute for Systems Biology and
	Medicine, CNRS-ENS-UCBL-INSERM, Lyon,
Middelvold P. I.M.	France Contro for Allorer Recover Karolinska
	Institutet Stockholm Sweden
Miralpeix M	Almirall, Barcelona, Spain.
Montuschi P	Università Cattolica del Sacro Cuore. Milan. Italy:
	,

Murray C S	Division of infection, immunity and respiratory medicine, School of biological sciences, University of Manchester, Manchester University NHS Foundation Trust, and Manchester Academic Health Science Centre, Manchester, United
	Kingdom
Musial J	Dept. of Medicine, Jagiellonian University Medical College, Krakow, Poland
Mumby S	National Heart and Lung Institute Imperial
Mulliby, S	College, London, UK
Myles D	Respiratory Therapeutic Unit, GSK, London, UK:
Nordlund B	Dept. Women's and Children's Health & Centre
	for Allergy Research, Karolinska Institutet,
	Stockholm, Sweden
Pandis I	Data Science Institute, Imperial College, London,
	UK
Pavlidis S	National Heart and Lung Institute, Imperial
	College, London, UK
Postle A	University of Southampton, UK
Powel P	European Lung Foundation, Sheffield, UK;
Praticò G	CROMSOURCE, Verona, Italy
Puig Valls M	CROMSOURCE, Barcelona, Spain
Rao N	Janssen R&D, LLC, Spring House, PA, USA
Reinke S	Institute of Environmental Medicine, Karolinska
	Institutet, Stockoholm, Sweden
Riley J	Respiratory Therapeutic Unit, GSK, London, UK;
Roberts A	Asthma UK, London, UK;
Roberts G	NIHR Southampton Respiratory Biomedical
	Research Unit, Clinical and Experimental
	Sciences and Human Development and Health,
Dowo A	Jangeon PfrD, UK,
Rowe A Sandström T	Dopt of Public Health and Clinical Medicine
Sandstrom 1	Umeå University. Umeå. Sweden:
Schofield JPR	Centre for Proteomic Research, Institute for Life
	Sciences, University of Southampton,
	Southampton, UK
Seibold W	Boehringer Ingelheim Pharma GmbH, Biberach,
	Germany
Shaw D E	Respiratory Research Unit, University of
	Nottingham, UK;
Sigmund R	Boehringer Ingelheim Pharma GmbH & Co. KG;
	Biberach, Germany
Singer F	Pediatric Respiratory Medicine, Department of
	Pediatrics, Inselspital, Bern University Hospital,
	University of Bern, Bern, Switzerland.
Skipp P J	Centre for Proteomic Research, Institute for Life
	Sciences, University of Southampton,
С : I . М	Southampton, UK
Smicker M	Sanon, Cambridge, USA
Sousa A K	Respiratory Therapeutic Unit, GSK, London, UK;

Sparreman-Mikus M	Department of Medicine Huddinge, Karolinska Institutet, and Department of Respiratory
	Medicine, Karolinska University Hospital,
	Stockholm, Sweden
Sterk P J	Academic Medical Centre, University of
	Amsterdam, Amsterdam, The Netherlands;
Ström M	Department of Medicine Solna, Karolinska
0 1/	Institutet, Stockholm, Sweden
Sun K	Data Science Institute, Imperial College, London,
Thornton P	UK MCD LICA
Inormon D Uddin M	MSD, USA AstroZonogo BioPharmagouticals B&D
	$Astrazeneca Dior narmaceuticais \Lambda \& D,Cothonburg, Sweden$
Vorsi A	National Heart and Lung Institute Imperial
	College London JIK
Vestbo J	Centre for Respiratory Medicine and Allergy
	Institute of Inflammation and Repair. University
	of Manchester and University Hospital of South
	Manchester, Manchester Academic Health
	Sciences Centre, Manchester, United Kingdom
Vissing N H	COPSAC, Copenhagen Prospective Studies on
	Asthma in Childhood, Herlev and Gentofte
	Hospital, University of Copenhagen, Copenhagen,
	Denmark;
Wagers S S	BioSci Consulting, Maasmechelen, Belgium
Wheelock A	Respiratory Medicine Unit, Department of
	Medicine Solna and Center for Molecular
	Medicine, Karolinska Institutet, Stockholm,
	Sweden; and Department of Respiratory Medicine
	Stockholm Swodon:
Wheelock C E	Institute of Environmental Medicine, Centre for
	Allergy Research, Karolinska Institutet.
	Stockholm, Sweden:
Wilson S J	Histochemistry Research Unit, Faculty of
	Medicine, University of Southampton,
	Southampton, UK;
Yasinska V	Department of Medicine Huddinge, Karolinska
	Institutet, and Department of Respiratory
	Medicine, Karolinska University Hospital,
	Stockholm, Sweden
Zounemat Kermani, N	Data Science Institute, Imperial College, London,
	UK

Contributors

IMA, PJS & KFC conceived the idea; IMA, KFC, PJS & RD obtained the funding for U-BIOPRED project; SB, JR, PH obtained the funding for the metagenomic analysis; SB, JR, PH, IMA, SHC, AV & KFC discussed the approach to data analysis; .AV, FXI, MIA, NZK analysed the data; AV, FXI & KFC wrote the manuscript; all authors contributed to its finalisation and agreed with the final version for submission.

All authors gave final approval of the manuscript, had full access to all the data in the study, and had final

responsibility for the decision to submit for publication.

Declaration of interests

Dr Chotirmall has received lecture fees from Astra-Zeneca, serves on advisory boards for Boehringer-Ingelheim, CSL Behring and Pneumagen Ltd. and is on Data and Safety Monitoring Boards (DSMB) for Inovio Pharmaceuticals and Imam Abdulrahman Bin Faisal University all outside of the submitted work. Dr Maitland-van der Zee has received grants from Health Holland and she is the PI of a P4O2 (Precision Medicine for more Oxygen) public private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis), received unrestricted research grants from GSK, Boehringer Ingelheim and Vertex, received consulting fees paid to her institution from Boehringer Ingelheim and AstraZeneca, and received honoraria for lectures paid to her institution from GlaxoSmithKline; outside the submitted work. Dr. Dahlén reports personal fees from AZ, Cayman Chemicals, GSK, Novartis, Regeneron, Sanofi, TEVA, outside the submitted work. Dr Baribaud owns stock options from his former and current employer. Dr Sterk is scientific advisor and has an officially non-substantial share in the SME Breathomix that produces eNoses. Dr Chung has received honoraria for participating in Advisory Board meetings of Roche, Merck, Shionogi and Rickett-Beckinson and has also been renumerated for speaking engagements for Novartis and AZ. Dr Rilev worked for and had shares in GSK. Dr. Bates reports to be an employee of Johnson & Johnson and to have previously worked and holds stock in GSK. Dr Djukanovic declares consulting fees from Synairgen, Sanofi and Galapagos, lecture fees from GSK, AZ and Airways Vista and he holds shares from Synairgen. Dr Howarth is an employee of GSK. Dr Montuschi, Dr Kermani, Dr Adcock, Dr Ivan, Dr Abdel-Aziz and Mr Versi have nothing to declare.

Legend to Figures:

Figure 1. Airway of severe asthma subjects exhibits distinct species-level microbiome profiles. (A) Barplot showing the average species-level airway microbiome profiles across study cohorts. (B) Boxplot illustrating species-level α -diversity of airway microbiome across study cohorts. (C) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species across study cohorts. (D) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species across study cohorts. (D) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species between the 4 groups of San, SAs/ex, MMA and HC. Significance: ns (not significant, P > 0.05), *P [?]0.05, **P [?]0.01 and ***P [?]0.001. Study cohorts: SAn (non-smokers with severe asthma); SAs/ex (smokers or ex-smokers with severe asthma), MMA (non-smokers with mild or moderate asthma) and HC (healthy controls).

Figure 2. Sputum inflammation type shows distinct species-level microbiome profiles. (A) Barplot showing the average species-level airway microbiome profiles according to granulocytic sputum inflammation type. (B) Boxplot illustrating species-level [?]-diversity of airway microbiome according to granulocytic sputum inflammation type. (C) Principle coordinate analysis (PCoA) based on Bray-Curtis dissimilarity illustrating species-level β -diversity of airway microbiomes in the 4 granulocytic sputum inflammation types and HC. (D) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species according to granulocytic sputum inflammation type. (E) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species between each of the sputum granulocytic types and healthy control. Significance: ns (not significant, P > 0.05), *P[?] 0.05, **P[?] 0.01 and ***P[?] 0.001. Granulocytic sputum inflammation type: EOS: eosinophilic high (sputum eosinophil % [?] 1.49%); NEU: neutrophilic high (sputum neutrophil count % [?] 73.6%); MIX: both neutrophilic and eosinophilic high; PAU: paucigranulocytic (sputum eosinophil % < 1.49% and sputum neutrophil count % < 73.6%) and HC (healthy controls).

Figure 3. Molecular phenotypes of asthma exhibit distinct microbiome profiles. (A) Barplot showing the average species-level airway microbiome profiles across the 3 transcriptome-associated molecular phenotypes (TACs) and in healthy controls (HC). (B) Boxplot illustrating species-level α -diversity of airway microbiome across the TACs and HC. (C) Principle coordinate analysis (PCoA) based on Bray-

Curtis dissimilarity illustrating species-level β -diversity of airway microbiomes in the 3 TACs and HC (D) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species between the 3 TACs (E) Barplots showing log2 fold-change of significantly differentially abundant airway microbial species between each TAC and HCs. Significance: ns (not significant, P > 0.05), *P [?]0.05, **P [?]0.01 and ***P [?]0.001.

Figure 4. Heatmap of Spearman's correlation coefficients between FEV1 (% predicted), FEV1/FVC ratio, exacerbations in previous year, sputum neutrophil and eosinophil cell counts (%), blood neutrophil and eosinophil counts, and fractional exhaled nitric oxide (FeNO) levels against the abundance of top bacterial species for the 3 asthma cohorts. Significance of Spearman coefficient correlation: ns - not significant (adjusted p > 0.05), with clear box; *adjusted p [?] 0.05; **adjusted p [?] 0.01; ***adjusted p [?] 0.001. SAn: non-smokers with severe asthma; SAs/ex: smokers or ex-smokers with severe asthma; MMA: mild-moderate non-smoking asthma; HC: healthy non-smoking and non-asthmatic.

Figure 5. Airway of severe asthma subjects exhibits temporal stability in species-level microbiome profiles. (A) Barplots showing the baseline and longitudinal follow-up of species-level airway microbiome profiles in subjects with severe asthma, using the same order of subject identifiers. (B) Paired boxplot illustrating species-level α -diversity of airway microbiomes across in severe asthma cases. (C) Principle coordinate analysis (PCoA) based on Bray-Curtis dissimilarity illustrating species-level β -diversity of airway microbiomes at baseline or longitudinal follow-up. Paired samples that are from the same subject are connected by a line. (D) Boxplot showing the species-level microbial compositional similarity across possible sample pairing: Within BL (pairing between any two baseline samples), Within LT (pairing between any two longitudinal follow-up samples), Unpaired (pairing between baseline and longitudinal follow-up samples from different subjects), and paired (pairing between baseline and longitudinal samples from the same subject). Timepoint: BL (baseline) and LT (longitudinal follow-up). Significance: ns (not significant, P > 0.05), *P[?]0.05, **P [?]0.01 and ***P [?]0.001.

REFERENCES

1. Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649-59.

2. Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5).

3. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49(2): 1602135 .

4. Simpson JL, Phipps S, Baines KJ, Oreo KM, Gunawardhana L, Gibson PG. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J. 2014;43(4):1067-76.

5. Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, et al. Functional effects of the microbiota in chronic respiratory disease. The lancet Respiratory medicine. 2019;7(10):907-20.

6. Chung KF. Potential Role of the Lung Microbiome in Shaping Asthma Phenotypes. Annals of the American Thoracic Society. 2017;14(Supplement_5):S326-S31.

7. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PloS one. 2010;5(1):e8578.

8. Huang YJ, Nelson CE, Brodie EL, Desantis TZ, Baek MS, Liu J, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol. 2011;127(2):372-81.e1-3.

9. Green BJ, Wiriyachaiporn S, Grainge C, Rogers GB, Kehagia V, Lau L, et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PloS one.

2014;9(6):e100645.

10. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bonnelykke K, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357(15):1487-95.

11. Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, et al. The airway microbiome in patients with severe asthma: Associations with disease features and severity. J Allergy Clin Immunol. 2015;136(4):874-84.

12. Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, et al. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J. 2016;47(3):792-800.

13. Taylor SL, Leong LEX, Choo JM, Wesselingh S, Yang IA, Upham JW, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol. 2018;141(1):94-103 e15.

14. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49(2):443-55.

15. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308-21.

16. Rossios C, Pavlidis S, Hoda U, Kuo CH, Wiegman C, Russell K, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. J Allergy Clin Immunol. 2018;141(2):560-70.

17. Andrew S. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online]. 2010.

18. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 2012;9(4):357-9.

19. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics (Oxford, England). 2009;25(16):2078-9.

20. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics (Oxford, England). 2010;26(6):841-2.

21. Morgan M, Anders S, Lawrence M, Aboyoun P, Pagès H, Gentleman R. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics (Oxford, England). 2009;25(19):2607-8.

22. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature methods. 2015;12(10):902-3.

23. Morgat A, Coissac E, Coudert E, Axelsen KB, Keller G, Bairoch A, et al. UniPathway: a resource for the exploration and annotation of metabolic pathways. Nucleic Acids Res. 2012;40(Database issue):D761-9.

24. Oksanen J, Blanchet, F.G., Friendly, M., Kindt, R., Legendre, P. McGlinn, D. Minchin, P.R. O'Hara, R.B. Simpson, G.L. Solymos, P. Stevens, M.H.M. Szoecs, E. Wagner, H. Ordination methods, diversity analysis and other functions for community and vegetation ecologists. 2017.

25. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PloS one. 2013;8(4):e61217.

26. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

27. Liang Z, Zhang Q, Thomas CM, Chana KK, Gibeon D, Barnes PJ, et al. Impaired macrophage phagocytosis of bacteria in severe asthma. Respiratory research. 2014;15:72.

28. Clemans DL, Bauer RJ, Hanson JA, Hobbs MV, St Geme JW, 3rd, Marrs CF, et al. Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae. Infect Immun. 2000;68(8):4430-40.

29. Galdiero M, Galdiero M, Finamore E, Rossano F, Gambuzza M, Catania MR, et al. Haemophilus influenzae porin induces Toll-like receptor 2-mediated cytokine production in human monocytes and mouse macrophages. Infect Immun. 2004;72(2):1204-9.

30. Hassan F, Ren D, Zhang W, Merkel TJ, Gu XX. Moraxella catarrhalis activates murine macrophages through multiple toll like receptors and has reduced clearance in lungs from TLR4 mutant mice. PloS one. 2012;7(5):e37610.

31. Fink J, Mathaba LT, Stewart GA, Graham PT, Steer JH, Joyce DA, et al. Moraxella catarrhalis stimulates the release of proinflammatory cytokines and prostaglandin E from human respiratory epithelial cells and monocyte-derived macrophages. FEMS Immunol Med Microbiol. 2006;46(2):198-208.

32. N'Guessan PD, Temmesfeld-Wollbrück B, Zahlten J, Eitel J, Zabel S, Schmeck B, et al. Moraxella catarrhalis induces ERK- and NF-kappaB-dependent COX-2 and prostaglandin E2 in lung epithelium. Eur Respir J. 2007;30(3):443-51.

33. Bousbia S, Papazian L, Auffray JP, Fenollar F, Martin C, Li W, et al. Tropheryma whipplei in patients with pneumonia. Emerg Infect Dis. 2010;16(2):258-63.

34. Lozupone C, Cota-Gomez A, Palmer BE, Linderman DJ, Charlson ES, Sodergren E, et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med. 2013;187(10):1110-7.

35. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PloS one. 2011;6(2):e16384.

36. Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067-75.

37. Lim MY, Yoon HS, Rho M, Sung J, Song YM, Lee K, et al. Analysis of the association between host genetics, smoking, and sputum microbiota in healthy humans. Scientific reports. 2016;6:23745.

38. Denner DR, Sangwan N, Becker JB, Hogarth DK, Oldham J, Castillo J, et al. Corticosteroid therapy and airflow obstruction influence the bronchial microbiome, which is distinct from that of bronchoalveolar lavage in asthmatic airways. J Allergy Clin Immunol. 2016;137(5):1398-405 e3.

39. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med. 2013;188(10):1193-201.

40. Abdel-Aziz MI, Brinkman P, Vijverberg SJH, Neerincx AH, Riley JH, Bates S, et al. Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. Journal of Allergy and Clinical Immunology. 2021;147(1):123-34.

41. Kim YH, Jang H, Kim SY, Jung JH, Kim GE, Park MR, et al. Gram-negative microbiota is related to acute exacerbation in children with asthma. Clinical and translational allergy. 2021;11(8):e12069.

42. Abdel-Aziz MI, Vijverberg SJH, Neerincx AH, Brinkman P, Wagener AH, Riley JH, et al. A multiomics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. Eur Respir J. 2022;59(1).

43. Menzel P, Ng KL, Krogh A. Fast and sensitive taxonomic classification for metagenomics with Kaiju. Nat Commun. 2016;7:11257.











Figure 4

